Visit | Budesonide–formoterol ‘as needed’ | Budesonide maintenance two times per day | ||||
N | Well/partly controlled | Uncontrolled | N | Well/partly controlled | Uncontrolled | |
n/N (%) | n/N (%) | n/N (%) | n/N (%) | |||
Visit 1 (Baseline) | 220 | 167 (75.9) | 53 (24.1) | 225 | 162 (72.0) | 63 (28.0) |
Visit 2 (Week 6) | 208 | 165 (79.3) | 43 (20.7) | 206 | 180 (87.4) | 26 (12.6) |
Visit 3 (Week 12) | 198 | 162 (81.8) | 36 (18.2) | 203 | 177 (87.2) | 26 (12.8) |
Visit 4 (Week 22) | 183 | 153 (83.6) | 30 (16.4) | 182 | 163 (89.6) | 19 (10.4) |
Visit 5 (Week 32) | 174 | 143 (82.2) | 31 (17.8) | 171 | 151 (88.3) | 20 (11.7) |
Visit 6 (Week 42) | 170 | 140 (82.4) | 30 (17.7) | 155 | 130 (83.9) | 25 (16.1) |
Visit 7 (Week 52)* | 196 | 166 (84.3) | 31 (15.7) | 197 | 161 (81.7) | 36 (18.3) |
End of study (LOCF)† | 214 | 183 (85.5) | 31 (14.5) | 214 | 177 (82.7) | 37 (17.3) |
The definitions for GINA level of asthma control were based on the GINA report published in 2014.
*Visit 7 represents ACQ-5 scores collected at withdrawal from the study or at completion of the study (week 52)
†LOCF except if only a baseline reading was available; the number missing any observations after baseline was 6 for budesonide–formoterol ‘as needed’ and 11 for budesonide maintenance two times per day.
ACQ-5, Asthma Control Questionnaire Version 5; GINA, Global Initiative for Asthma; LOCF, last observation carried forward; N, number of patients in each treatment group at each visit; n, number of patients in each GINA category.